Czasopismo Clinical and Experimental Hepatology 2025

Review paper

Diagnosing and treating fatty liver disease: strategies for hepatocellular carcinoma and cardiovascular disease prevention

Toru Ishikawa

Clin Exp HEPATOL 2025; 11, 4: 307–312

DOI: https://doi.org/10.5114/ceh.2025.155228

Abstract View text (PDF)

Review paper

Potential pharmacotherapy pathways in metabolic dysfunction-associated steatotic liver disease

Paweł Rajewski, Jakub Cieściński, Piotr Rajewski, Szymon Suwała, Alicja Rajewska, Maciej Potasz

Clin Exp HEPATOL 2025; 11, 4: 313–323

DOI: https://doi.org/10.5114/ceh.2025.154956

Abstract View text

Review paper

Current approach to diagnosis and treatment of focal nodular hyperplasia in children with a management algorithm

Anna Chudoba, Joanna Pawłowska, Joanna Cielecka-Kuszyk, Dorota Majak, Irena Jankowska, Dorota Broniszczak-Czyszek, Jakub Barański, Piotr Czubkowski

Clin Exp HEPATOL 2025; 11, 4: 324–332

DOI: https://doi.org/10.5114/ceh.2025.155044

Abstract View text (PDF)

Review paper

Metabolic dysfunction-associated steatotic liver disease in children

Malgorzata Pawlowska

Clin Exp HEPATOL 2025; 11, 4: 333–336

DOI: https://doi.org/10.5114/ceh.2025.155319

Abstract View text (PDF)

Original paper

Annexin A2 as a marker for hepatocellular carcinoma detection among patients with hepatitis C virus-related liver cirrhosis after HCV treatment using directly acting antivirals

Mohamed S. Shater, Amr A. Abd Elmoety, Yousri A. A. Rostom, Eman Z. Elkemary, Hyam M. Helal, Ahmed Kamal

Clin Exp HEPATOL 2025; 11, 4: 337–343

DOI: https://doi.org/10.5114/ceh.2025.154172

Abstract View text (PDF)

Original paper

Pemafibrate as a therapeutic option for metabolic dysfunction-associated steatotic liver disease resistant to dietary intervention

Hideyuki Tamai, Jumpei Okamura

Clin Exp HEPATOL 2025; 11, 4: 344–351

DOI: https://doi.org/10.5114/ceh.2025.155314

Abstract View text (PDF)

Original paper

Associations between diffusion-weighted imaging and immunohistochemical features in hepatocellular carcinoma: a preliminary analysis of tumor-infiltrating lymphocytes and microvessel density expression

Daniele Romeo, Theresa Richter, Anne-Kathrin Höhn, Hans Michael Tautenhahn, Daniel Seehofer, Uwe Scheuermann, Timm Denecke, Hans-Jonas Meyer

Clin Exp HEPATOL 2025; 11, 4: 352–359

DOI: https://doi.org/10.5114/ceh.2025.155477

Abstract View text (PDF)

Original paper

Identification of novel therapeutic targets for liver fibrosis, cirrhosis, and hepatocellular carcinoma via dual-omics analysis and preliminary exploration of regulatory mechanisms

Jian Chen, Rongge Cao, Zhiyuan He, Zifan Li, Yanan Hong, Chuanzeng Ren, Ying Wang, Jiazhao Wu, Yongqing Liu, Honghai Xia

Clin Exp HEPATOL 2025; 11, 4: 360–370

DOI: https://doi.org/10.5114/ceh.2025.155448

Abstract View text (PDF)

Original paper

Association of thyroid function and thyroid hormone sensitivity with all-cause and cardiovascular mortality in euthyroid patients with MASLD

Xinghua Zhang, Xiaoling Xing, Sheng Mao, Min Qi, Yanrui Xin, Xinyu Ma, Rui Huang

Clin Exp HEPATOL 2025; 11, 4: 371–386

DOI: https://doi.org/10.5114/ceh.2025.155479

Abstract View text (PDF)

Original paper

Effect and prognostic factors of the double plasma molecular adsorption system combined with partial plasma exchange (DPMAS-PPE) in patients with liver failure

Xudong Liu, Xiaofang Zhao, Chunni Liang, Ruichao Fang, Yinying Liao, Qianjun Ren, Su Li, Yuqing Cheng, Xiaozu Meng, Weiqin Lu

Clin Exp HEPATOL 2025; 11, 4: 387–399

DOI: https://doi.org/10.5114/ceh.2025.154322

Abstract View text (PDF)

Diagnosing and treating fatty liver disease: strategies for hepatocellular carcinoma and cardiovascular disease prevention

Potential pharmacotherapy pathways in metabolic dysfunction-associated steatotic liver disease

Current approach to diagnosis and treatment of focal nodular hyperplasia in children with a management algorithm

Metabolic dysfunction-associated steatotic liver disease in children

Annexin A2 as a marker for hepatocellular carcinoma detection among patients with hepatitis C virus-related liver cirrhosis after HCV treatment using directly acting antivirals

Pemafibrate as a therapeutic option for metabolic dysfunction-associated steatotic liver disease resistant to dietary intervention

Associations between diffusion-weighted imaging and immunohistochemical features in hepatocellular carcinoma: a preliminary analysis of tumor-infiltrating lymphocytes and microvessel density expression

Identification of novel therapeutic targets for liver fibrosis, cirrhosis, and hepatocellular carcinoma via dual-omics analysis and preliminary exploration of regulatory mechanisms

Association of thyroid function and thyroid hormone sensitivity with all-cause and cardiovascular mortality in euthyroid patients with MASLD

Effect and prognostic factors of the double plasma molecular adsorption system combined with partial plasma exchange (DPMAS-PPE) in patients with liver failure

Coverage in

Integrated with

Editorial Policies